Schnitzler Syndrome Disease Treatment Market: How Is IL-1 Blockade Transforming Outcomes for This Rare Autoinflammatory Disorder?
Schnitzler syndrome — the late-onset autoinflammatory disease characterized by chronic urticarial rash, monoclonal IgM gammopathy, intermittent fever, bone pain, and elevated inflammatory markers — remained a diagnostic enigma and therapeutic challenge for decades until the discovery of interleukin-1β as the central pathogenic cytokine, with the Schnitzler Syndrome Disease...
0 Commenti 0 condivisioni 533 Views 0 Anteprima
SocioMint https://sociomint.com